First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP:TGF-ß1 complex, as monotherapy and in combination with the anti–PD-1 antibody budigalimab in patients with advanced solid tumors

First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP:TGF-ß1 complex, as monotherapy and in combination with the anti–PD-1 antibody budigalimab in patients with advanced solid tumors

BackgroundTransforming growth factor (TGF)-ß1 is a pleiotropic cytokine that can promote tumor growth and suppress antitumor immune responses. Latent TGF-ß1 associates with glycoprotein-A repetition predominant (GARP) on the surface of regulatory T cells prior to its activation and release. Livmonip...

Full description

Saved in:
Bibliographic Details
Main Authors: Toshio Shimizu, John Powderly, Albiruni Abdul Razak, Patricia LoRusso, Kathy D. Miller, Steven Kao, Sarah Kongpachith, Catherine Tribouley, Michelle Graham, Brian Stoll, Maulik Patel, Mohammad Sahtout, Martha Blaney, Rachel Leibman, Talia Golan, Anthony Tolcher
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-10-01
Series:Frontiers in Oncology
Subjects:
advanced solid tumors
TGF-ß1
GARP
immunotherapy
anti-PD-1 antibody
combination drug therapy
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2024.1376551/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2024.1376551/full

Similar Items